As of 25 April 2025, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of Ceftaroline Fosamil (600 mg powder for concentrate for solution for injection) for possible government financing. As such, the HTA Council hereby makes public its preliminary assessment that it does not recommend the government financing of continue reading : HTA Council Preliminary Recommendation on Ceftaroline Fosamil (600 mg powder for concentrate for solution for injection) in the Treatment of Community-Acquired Pneumonia (CAP) in Children
HTA Council Preliminary Recommendation on Coagulation Factor VIII and Factor VIII Inhibitor Bypassing Activity
As of 10 April 2025, the Health Technology Assessment Council hereby makes public its preliminary recommendations on the possible financing of the following health technologies by the Department of Health (DOH) and the Philippine Health Insurance Corporation (PhilHealth), for stakeholder feedback/comments. These health technologies were reviewed against clinical practice guidelines (CPGs) [local and approved by continue reading : HTA Council Preliminary Recommendation on Coagulation Factor VIII and Factor VIII Inhibitor Bypassing Activity
HTA Council Preliminary Recommendation on High-risk Human Papillomavirus (HPV) DNA Test and Visual Inspection with Acetic Acid
Update as of 13 March 2025: The public consultation and appeals period for the HTA Council’s Preliminary Recommendation on the (1) High-Risk Human Papillomavirus (HrHPV) DNA Test and (2) Visual Inspection with Acetic Acid (VIA) for cervical cancer screening in women aged 30–65 years ended on 25 February 2025. HTA Philippines received and processed one continue reading : HTA Council Preliminary Recommendation on High-risk Human Papillomavirus (HPV) DNA Test and Visual Inspection with Acetic Acid